Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

In the last few years, a great interest has emerged in investigating the pleiotropic effects of
Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Protein and peptide therapeutics require parenteral administration, which can be a deterrent
to medication adherence. For this reason, there have been extensive efforts to develop …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects
relevant to the chronic complications of type 2 diabetes. Although GLP-1RAs attenuate T cell …

Abstract Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and
body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the …